Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Pancreatic Neoplasms 4 Breast Neoplasms 3 Melanoma 2 Colorectal Neoplasms 2 Untreated Resectable Pancreatic Adenocarcinoma 1 Resectable Localized Prostate Cancer 1 Prostatic Neoplasms 1 Prostate Cancer Recurrent 1 Pancreatic Ductal Adenocarcinoma 1 Ovarian Neoplasms 1 Osteosarcoma 1 Neoplasms 1 Neoplasm, Residual 1 Liver Neoplasms 1 Klatskin Tumor 1 Hormone Receptor-Positive and HER2-Negative Advanced Breast Cancer 1 Glioma 1 Gastrointestinal Neoplasms 1 Cholangiocarcinoma 1 Carcinoma, Renal Cell 1 Carcinoma, Non-Small-Cell Lung 1 Carcinoma, Hepatocellular 1 Adenocarcinoma 1

Interventions

Paclitaxel 69 Bevacizumab 62 Carboplatin 53 pembrolizumab 46 olaparib 32 Specimen Handling 27 Gemcitabine 27 Cyclophosphamide 26 Magnetic Resonance Spectroscopy 24 liposomal doxorubicin 22 Cisplatin 21 niraparib 20 Taxes 18 Nivolumab 18 fludarabine 17 Topotecan 17 Biopsy 17 Doxorubicin 14 Immunoglobulin G 12 Fulvestrant 12 Disulfides 12 Oxaliplatin 10 mirvetuximab soravtansine 9 durvalumab 9 aldesleukin 9 Surveys and Questionnaires 9 Ipilimumab 9 Fluorouracil 9 Blood Specimen Collection 9 cemiplimab 8

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Ovarian Neoplasms × Hydroxychloroquine × 1 year × Clear all

NCT06971744 2025-12-22

Autophagy Maintenance (AUTOMAIN)

Medical University of South Carolina

Phase 2 Recruiting

Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡